Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CLDN18.2 UCAR-T cell injection
- Development stage
- Unknown
- Lead developer
- Suzhou Maximum Bio-tech
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CLDN18.2 UCAR-T cell injection is an investigational allogeneic (universal/off-the-shelf) chimeric antigen receptor T-cell (CAR-T) therapy. It is being developed by Zhongshan People's Hospital for the treatment of advanced solid tumors, specifically gastric and gastroesophageal junction (GEJ) cancers. The therapy consists of donor-derived T cells engineered to express a chimeric antigen receptor (CAR) targeting Claudin 18.2 (CLDN18.2), a tight junction protein frequently overexpressed in gastric malignancies. As an allogeneic product, it is derived from healthy donor cells rather than the patient's own, potentially allowing for immediate availability and reduced manufacturing complexity compared to autologous CAR-T therapies. It is currently being evaluated in early-phase clinical trials in China to assess safety, tolerability, and preliminary efficacy.
- Other names
- CLDN18.2 CAR-T cell injectionCLDN-18.2 CAR-T cell injectionCLDN 18.2 CAR-T cell injectionCLDN18.2 UCAR-TCLDN-18.2 UCAR-TCLDN 18.2 UCAR-T
02
Targets
Claudin 18.2
Beyond the preview
Go deeper on CLDN18.2 UCAR-T cell injection.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CLDN18.2 UCAR-T cell injection.